Janssen R&D announced results from a Phase 3 study on the use of initial combination therapy of canagliflozin and metformin extended release (XR) in type 2 diabetes patients with higher A1C levels and ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-daily, fixed-dose combination therapy of the SGLT2 inhibitor canagliflozin and ...
February 2, 2010 (UPDATED February 26, 2010) — Metformin hydrochloride extended release (XR) with lifestyle intervention may be helpful for the treatment of adolescent obesity, according to the ...
Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE ™ XR (saxagliptin and metformin HCl extended-release), ...
SAN DIEGO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from two 24-week Phase 3 clinical studies examining the investigational ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...
Whitehouse Station, NJ - Merck announced on February 2, 2012 that the US Food and Drug Administration (FDA) has approved Janumet XR (sitagliptin and extended-release metformin hydrochloride) tablets ...
JANUMET XR (sitagliptin and metformin HCl extended-release) 50mg/1000mg;100mg/1000mgtablets by Merck Merck announced that the FDA has approved Janumet XR (sitagliptin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback